Moberg Pharma issues a bond loan in the amount of SEK 300 million on the Nordic bond market to finance growth and acquisitions

STOCKHOLM, January 25th, 2016. Moberg Pharma AB (OMX: MOB) announces that the
company has decided to issue a five-year senior unsecured bond loan in the
amount of SEK 300 million with maturity on January 29th, 2021.
The bond loan will give a floating rate coupon of Stibor 3m + 6.00% and have a
total framework amount of SEK 600 million. Moberg Pharma intends to apply for
listing of the bond loan on Nasdaq Stockholm within 30 days.

To enable future growth, Moberg Pharma intends to make significant investments
during 2016, focusing on strengthening brand platforms for the company’s
strategic brands in the U.S., increased international distribution, acquiring
additional brands and initiating Phase III studies for MOB-015.

Carnegie Investment Bank and Swedbank have acted as financial advisors and
Gernandt & Danielsson has acted as legal advisor in the transaction.

”We are pleased with the large interest among Swedish and Nordic investors for
the bond loan, despite challenging market conditions. The access to the
corporate bond market and non-dilutive financing strengthens our financial
position further and is an important step in the financing of the company’s
growth and acquisition strategy”, says Peter Wolpert, CEO Moberg Pharma.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 08:00 am (CET) on January 25th, 2016.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 707 35 71 35, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Domeboro®, Jointflex®, Vanquish®, and Fergon®. Kerasal
Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail
disorders in the U.S., Canada and several EU markets and is currently being
launched in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focuses on innovative drug
delivery of proven compounds and include two phase II assets, MOB-015
(onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in
Stockholm and New Jersey and the company’s shares are listed on the Small Cap
list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further
information, please visit: www.mobergpharma.com.